|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen S, Chen JZ, Zhang JQ, Chen HX, Qiu
FN, Yan ML, Tian YF, Peng CH, Shen BY, Chen YL and Wang YD:
Silencing of long noncoding RNA LINC00958 prevents tumor initiation
of pancreatic cancer by acting as a sponge of microRNA-330-5p to
down-regulate PAX8. Cancer Lett. 446:49–61. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang G, Pan J, Zhang L, Wei Y and Wang C:
Long non-coding RNA CRNDE sponges miR-384 to promote proliferation
and metastasis of pancreatic cancer cells through upregulating
IRS1. Cell Prolif. 50:2017. View Article : Google Scholar
|
|
5
|
Chang J and Erler J: Hypoxia-mediated
metastasis. Adv Exp Med Biol. 772:55–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lv WL, Liu Q, An JH and Song XY:
Scutellarin inhibits hypoxia-induced epithelial-mesenchymal
transition in bladder cancer cells. J Cell Physiol.
234:23169–23175. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Erkan M, Kurtoglu M and Kleeff J: The role
of hypoxia in pancreatic cancer: A potential therapeutic target?
Expert Rev Gastroenterol Hepatol. 10:301–316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y,
Liu QH, Shi M, Ni CR and Zhu MH: Upregulation of miR-194
contributes to tumor growth and progression in pancreatic ductal
adenocarcinoma. Oncol Rep. 31:1157–1164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abue M, Yokoyama M, Shibuya R, Tamai K,
Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K
and Satoh K: Circulating miR-483-3p and miR-21 is highly expressed
in plasma of pancreatic cancer. Int J Oncol. 46:539–547. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B,
Zhou L, Song WJ and Dou KF: MicroRNA-135a inhibits cell
proliferation by targeting Bmi1 in pancreatic ductal
adenocarcinoma. Int J Biol Sci. 10:733–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai
HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT and Chen CJ: High
PD-L1 expression correlates with metastasis and poor prognosis in
oral squamous cell carcinoma. PLoS One. 10:e01426562015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang HB, Yao H, Li CS, Liang LX, Zhang Y,
Chen YX, Fang JY and Xu J: Rise of PD-L1 expression during
metastasis of colorectal cancer: Implications for immunotherapy. J
Dig Dis. 18:574–581. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Chen L, Xiong Y, Zheng X, Xie Q,
Zhou Q, Shi L, Wu C, Jiang J and Wang H: Knockdown of PD-L1 in
human gastric cancer cells inhibits tumor progression and improves
the cytotoxic sensitivity to CIK therapy. Cell Physiol Biochem.
41:907–920. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XL, Xu LL and Wang F:
Hsa_circ_0020397 regulates colorectal cancer cell viability,
apoptosis and invasion by promoting the expression of the miR-138
targets TERT and PD-L1. Cell Biol Int. 41:1056–1064. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brahmer JR: PD-1-targeted immunotherapy:
Recent clinical findings. Clin Adv Hematol Oncol. 10:674–675.
2012.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Gao F, Zhou L, Wang H, Shi G and
Tan X: UCA1 regulates the growth and metastasis of pancreatic
cancer by sponging miR-135a. Oncol Res. 25:1529–1541. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fogel EL, Shahda S, Sandrasegaran K,
DeWitt J, Easler JJ, Agarwal DM, Eagleson M, Zyromski NJ, House MG,
Ellsworth S, et al: A multidisciplinary approach to pancreas cancer
in 2016: A review. Am J Gastroenterol. 112:537–554. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Landi S: Genetic predisposition and
environmental risk factors to pancreatic cancer: A review of the
literature. Mutat Res. 681:299–307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kubo T, Ninomiya T, Hotta K, Kozuki T,
Toyooka S, Okada H, Fujiwara T, Udono H and Kiura K: Study
protocol: Phase-Ib trial of nivolumab combined with metformin for
refractory/recurrent solid tumors. Clin Lung Cancer. 19:e861–e864.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo G, Xia X, Wang X, Zhang K, Cao J,
Jiang T, Zhao Q and Qiu Z: miR-301a plays a pivotal role in
hypoxia-induced gemcitabine resistance in pancreatic cancer. Exp
Cell Res. 369:120–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mace TA, Collins AL, Wojcik SE, Croce CM,
Lesinski GB and Bloomston M: Hypoxia induces the overexpression of
microRNA-21 in pancreatic cancer cells. J Surg Res. 184:855–860.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yue H, Liu L and Song Z: miR-212 regulated
by HIF-1α promotes the progression of pancreatic cancer. Exp Ther
Med. 17:2359–2365. 2019.PubMed/NCBI
|
|
28
|
Zhu G, Zhou L, Liu H, Shan Y and Zhang X:
MicroRNA-224 promotes pancreatic cancer cell proliferation and
migration by targeting the TXNIP-mediated HIF1α pathway. Cell
Physiol Biochem. 48:1735–1746. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abdelmohsen K, Kim MM, Srikantan S,
Mercken EM, Brennan SE, Wilson GM, Cabo Rd and Gorospe M: miR-519
suppresses tumor growth by reducing HuR levels. Cell Cycle.
9:1354–1359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu G, Zhang T, Jing Y, Bao Q, Tang Q and
Zhang Y: miR-519 suppresses nasopharyngeal carcinoma cell
proliferation by targeting oncogene URG4/URGCP. Life Sci.
175:47–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Royal RE, Levy C, Turner K, Mathur A,
Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and
Rosenberg SA: Phase 2 trial of single agent Ipilimumab
(anti-CTLA-4) for locally advanced or metastatic pancreatic
adenocarcinoma. J Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Le DT, Lutz E, Uram JN, Sugar EA, Onners
B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM and Laheru
DA: Evaluation of ipilimumab in combination with allogeneic
pancreatic tumor cells transfected with a GM-CSF gene in previously
treated pancreatic cancer. J Immunother. 36:382–389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Feng M, Xiong G, Cao Z, Yang G, Zheng S,
Song X, You L, Zheng L, Zhang T and Zhao Y: PD-1/PD-L1 and
immunotherapy for pancreatic cancer. Cancer Lett. 407:57–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Azad A, Yin Lim S, D'Costa Z, Jones K,
Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, et al:
PD-L1 blockade enhances response of pancreatic ductal
adenocarcinoma to radiotherapy. EMBO Mol Med. 9:167–180. 2017.
View Article : Google Scholar : PubMed/NCBI
|
